|
Slovenia Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
The Slovenia Pharmaceuticals and Healthcare Report
Independent 5-year pharmaceutical and healthcare industry forecasts for Slovenia.
Original pharmaceutical and healthcare market research and pharmaceutical and healthcare sector trend analysis for the Slovenian pharmaceutical and healthcare industry.
Competitive intelligence, Slovenian pharmaceutical and healthcare company rankings and SWOT analyses on international and domestic pharmaceutical and healthcare companies in the Slovenian market.
The Slovenia Pharmaceuticals and Healthcare Report has been researched at source and features the latest available data and forecasts to end- covering drugs and healthcare expenditure, the prescription, OTC and generics markets, and foreign trade; company rankings and competitive landscapes including multinational and national drugs companies; and analysis of latest industry news, trends and regulatory developments.
Business Monitor International’s Slovenia Pharmaceuticals and Healthcare Report provides industry professionals, market investors and corporate and financial services analysts with independent forecasts and competitive intelligence on the Slovenian pharmaceutical and healthcare industry.
Key Benefits of Report
- Benchmark BMI’s Independent 5-year Pharmaceutical and Healthcare Industry Forecasts on Slovenia to test other views – a key input for successful budgeting and strategic business planning in the Slovenian pharmaceutical and healthcare market.
- Target Business Opportunities & Risks in the Slovenian Pharmaceutical and Healthcare Sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Slovenia.
- Exploit The Latest Competitive Slovenian Pharmaceutical and Healthcare Intelligence & company SWOTS on your competitors and peers through company rankings by sales, market share and ownership structure – includes multi-national and national companies in Slovenia.
Coverage
Executive Summary & Industry SWOT
An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI’s forecast analysis, and taken together with BMI’s Economic and Business Environment SWOTS, give a complete overview of market climate.
Market Summary
Outline of market characteristics, growth factors, leading therapeutic segments and a competitivness of the market.
Regulatory Regime
Guide to and analysis of country intellectual property developments and pricing & reimbursement issues, which constitute the regulatory make-up of the market.
Industry Developments
Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D and patent legislation.
BMI 5-Year Industry Forecast
5-Year Forecasts to end- for all key industry indicators (see list below), supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:
- Drug market expenditure (US$bn); drug expenditure per capita (US$); as % of gdp
- Prescription drug market (US$bn)/as % of total market; sales by alimentary tract/metabolism; antibiotics, cardiovascular, central nervous system, oncology, musculoskeletal and respiratory system
- OTC market (US$bn)/as % of total market (sales by analgesic, cough and cold, digestives, skin treatments, vitamins and minerals)
- Generics market (US$bn)/ as % of total market
- Health expenditure (US$bn, % of gdp and per capita); public sector health expenditure as % of total; number of hospitals; beds, hospital admissions, doctors, births and deaths per 000 population
Forecasts based on bespoke BMI economic modelling, using historical data sets of macroeconomic and industry variables to derive rigorous statistical relationships, anchored in advanced linear regression techniques.
BMI 5-Year Macroeconomic Forecasts
BMI forecasts for all headline macroeconomic indicators, including:
Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt
Competitive Landscape & Profiles
Intelligence on the market position of major MNC power houses and indigenous companies. BMI profiles key research-based companies. Company SWOTS are provided for all key strategic players, complete with a company activity overview, its leading products and analysis of business opportunities.
|
Slovenia Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Chapter - Executive Summary |
| SWOT Analysis |
| Slovenia Pharmaceuticals And Healthcare Industry SWOT |
| Slovenia Political SWOT |
| Slovenia Economic SWOT |
| Slovenia Business Environment SWOT |
Chapter - Pharmaceutical Business Environment Ratings |
| Table: Regional Pharma Business Environment Ratings |
| Limits Of Potential Returns |
| Risks To Realisation Of Returns |
Chapter - Market Summary |
| Regulatory Regime |
| Recent EU-Wide Regulatory Developments |
| Intellectual Property Regime |
| IP Deficiencies |
| Patent Disputes |
| Pricing System |
| Reimbursement Policies |
| Eurozone Entry |
Chapter - Industry Developments |
| Epidemiology |
| Table: Leading Causes Of Death In Slovenia, 2002 |
| Healthcare Sector |
| Healthcare Provision Developments |
| Healthcare Insurance |
| Healthcare Expenditure |
| Pharmaceutical Industry |
| Recent Industry Developments |
| Clinical Trials |
| Medical Devices |
Chapter - Industry Forecast Scenario |
| Overall Market Forecast |
| Table: Slovenia – Drug Expenditure Indicators, Historical Data and Forecasts |
| Key Growth Factors – Industry |
| Table: Slovenia – Health Expenditure Indicators, Historical Data and Forecasts |
| Macroeconomic Forecast Scenario |
| Table: Slovenia - Economic Activity |
| Prescription Market Forecast |
| Table: Slovenia – Prescription Market Indicators, Historical Data and Forecasts (EURmn unless otherwise stated) |
| Patented Market Forecast |
| Table: Slovenia – Patented Drug Market Indicators, Historical Data And Forecasts |
| Generics Markets Forecast |
| Table: Slovenia - Generic Drug Market Indicators, Historical Data and Forecasts |
| OTC Market Forecasts |
| Table: Slovenia – OTC Market Indicators, Historical Data and Forecasts (EURmn unless otherwise stated) |
| Table: Slovenia – Pharmaceutical Trade Indicators, Historical Data and Forecasts (US$mn unless otherwise stated) |
| Other Healthcare Data Forecasts |
| Table: Slovenia – Other Health Indicators, Historical Data And Forecasts |
| Key Risks To BMI's Forecast Scenario |
Chapter - Competitive Landscape |
| Table: Leading Companies In Slovenia. 2007 |
Chapter - Company Profiles |
| Multinational Company Profiles |
| GlaxoSmithKline |
| Sanofi-Aventis |
| Pfizer |
| Novartis |
| Merck & Co |
| Indigenous Company Profiles |
| Krka |
| Lek (Novartis/Sandoz) |
Chapter - Country Snapshot: Slovenia Demographic Data |
| Section 1: Population |
| Table: Demographic Indicators, 2005-2030 |
| Table: Rural/Urban Breakdown, 2005-2030 |
| Section 2: Education And Healthcare |
| Table: Education, 2002-2005 |
| Table: Vital Statistics, 2005-2030 |
| Section 3: Labour Market And Spending Power |
| Table: Employment Indicators, 2001-2006 |
| Table: Consumer Expenditure, 2000-2012 (US$) |
| Table: Average Annual Wages, 2000-2012 |
Chapter - BMI Forecast Modelling |
| How We Generate Our Pharmaceutical Industry Forecasts |
| Pharmaceutical Business Environment Ratings Methodology |
| Ratings Overview |
| Table: Pharmaceutical Business Environment Indicators |
| Weighting |
| Table: Weighting Of Components |
| Sources |
|
Slovenia Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
In the BMI’s Business Environment Ranking table adjusted for Q209, Slovenia continued to improve its position in the matrix, rising by one place in relation to the previous period to 11th, out of the 20 main markets surveyed in Central and Eastern Europe (CEE). Despite its small population, Slovenia has one of the most advanced pharmaceutical markets in CEE, mainly due to the relative wealth of the country, a long tradition of pharmaceutical manufacturing and a high level of connection with Western Europe in general.
However, Slovenia’s pharmaceutical rating continues to be weighed down by a small market size and low forecast growth, although the high per capita GDP, well-developed healthcare services and widespread health awareness play in favour of pharmaceutical companies. Consequently, the rising demand for novel medicines can be expected to be one of the key drivers of pharmaceutical growth over the forecast period, in combination with an increased focus on private insurance and out-of-pocket spending, given the need for cost-containment within the state-supported mandatory insurance system. Over the next five years, the Slovenian pharmaceutical market is forecast to experience a compound annual growth rate (CAGR) of 3.84% (in local currency terms), reaching some EUR617mn (US$781mn) by 2013, which is still small by global, and even regional, standards.
In terms of industry developments, leading Slovenian drug maker Krka posted a 22% year-on-year (y-oy) increase in its 2008 Group sales, to EUR949.9mn (US$1.22bn), with net profit expected to match the planned EUR160mn (US$205.9mn). The majority of all sales continued to be achieved outside Slovenia, as the company’s domestic sales experienced a small annual rise of 3%, totalling EUR104.4mn (US$134.4mn). In contrast, Krka’s sales in Western Europe and overseas markets rose by 39%, as the company benefitted from the recent acquisition of German generics marker TAD Pharma and the Austrian pharmaceutical company Alternova Arzneimittel GmbH. In the meantime, Krka continues to invest in research and development (R&D), increasing its investment by 47% y-o-y to over US$120mn in the first nine months of 2008.
In the meantime, the European Parliament adopted a European Commission (EC) proposal that aims to harmonise rules and procedures for making changes to marketing authorisations. The directive amendment would make all medicines – including those authorised through a national approval route – subject to a single set of legislation across the whole of the European Union (EU). The proposal has been welcomed by the European Federation of Pharmaceutical Industries and Associations (EFPIA), the European Vaccine Manufacturers (EVM) and the European Biopharmaceutical Enterprises (EBE), which are hoping that the elimination of Bloc-wide variations in national rules. The changes have a potential to benefit multinationals in particular (which would increase competition to Slovenian drug makers), as large foreign companies already favour the centralised marketing approval procedure. The reduction of registration costs would allow more funds for marketing but also possibly have an impact on launch prices, with a view to making them more affordable to national markets.
|
Slovenia Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Africa |
| Algeria, Egypt, Kenya, Morocco, Nigeria, South Africa and Zimbabwe |
Asia |
| Australia, Bangladesh, China, Hong Kong, India, Indonesia, Japan, Malaysia, Pakistan, Philippines, Singapore, South Korea, Taiwan, Thailand and Vietnam |
Caribbean |
| Puerto Rico |
Europe |
| Belarus, Belgium, Bulgaria, Croatia, Czech Republic, Estonia, France, Germany, Greece, Hungary, Italy, Kazakhstan, Latvia, Lithuania, Moldova, Netherlands, Poland, Portugal, Romania, Russia, Serbia, Slovakia, Spain, Switzerland, Ukraine, United Kingdom and Uzbekistan |
Latin America |
| Argentina, Brazil, Chile, Colombia, Mexico, Peru and Venezuela |
Middle East |
| Bahrain, Iran, Israel, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, Turkey and United Arab Emirates |
North America |
| Canada and United States |
Business Monitor InternationalA Market Leader in Country Risk, Industry Intelligence and Company Research Mermaid House, 2 Puddle Dock, Blackfriars, London EC4V 3DS, UK |
BUSINESS MONITOR INTERNATIONAL's country risk analysis and forecasts, market research on leading industries, and multinational company research is relied upon by corporates, banks, government departments and multilateral organisations in over 125 countries around the world. Country Risk Analysis and Forecasts Industry Intelligence and Market Research Company Research |